Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZGNX Zogenix (ZGNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Zogenix Stock (NASDAQ:ZGNX) 30 days 90 days 365 days Advanced Chart Ad Stansberry Research25-Yr Wall St Legend: Get Out of Cash before Nov 6Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. Get Zogenix alerts:Sign Up Key Stats Today's Range$26.68▼$26.6850-Day Range$26.10▼$26.6852-Week Range$11.03▼$26.90Volume94 shsAverage Volume3.76 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.Read More… 25-Yr Wall St Legend: Get Out of Cash before Nov 6 (Ad)Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. Receive ZGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter. Email Address ZGNX Stock News HeadlinesNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comNext opportunity for crypto millionsOctober isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…October 7, 2024 | Crypto 101 Media (Ad)Alcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 21, 2023 | morningstar.comHow Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business WireOctober 11, 2022 | businesswire.comBiocryst PharmaceuticalsSeptember 30, 2022 | forbes.comNippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.comSeptember 26, 2022 | marketscreener.comSee More Headlines ZGNX Stock Analysis - Frequently Asked Questions How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) released its earnings results on Thursday, November, 4th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.08. Zogenix's revenue for the quarter was up 690.6% compared to the same quarter last year. What other stocks do shareholders of Zogenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD) and Company Calendar Last Earnings11/04/2021Today10/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZGNX CUSIP98978L10 CIK1375151 Webwww.zogenix.com Phone(510) 550-8300Fax858-259-1166Employees218Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,380,000.00 Net Margins-278.38% Pretax Margin-278.26% Return on Equity-91.20% Return on Assets-43.60% Debt Debt-to-Equity Ratio0.88 Current Ratio3.63 Quick Ratio4.74 Sales & Book Value Annual Sales$81.69 million Price / Sales18.36 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book4.02Miscellaneous Outstanding Shares56,227,000Free Float53,922,000Market Cap$1.50 billion OptionableOptionable Beta0.89 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ZGNX) was last updated on 10/7/2024 by MarketBeat.com Staff From Our PartnersBiden Deploys Phase 1 Fednow Digital CurrencyIf Kamala can steal the election…She'll steal your financial freedom next.American Alternative | SponsoredStrikes and Economic Unrest: Are You Prepared for What’s Coming?The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to ...InvestorPlace | Sponsored10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNew President Kamala warningFinancial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on ...Stansberry Research | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.